AI assistant
ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2023
Jan 12, 2023
31071_dirs_2023-01-11_064edb6a-622a-45d5-810d-31d774ea9905.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2023-01-09
Reporting Person: Waddill William D. (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-01-09 | Common Stock | S | 3200 | $30.00 | Disposed | 28950 | Direct |
| 2023-01-10 | Common Stock | A | 7867 | $0.00 | Acquired | 36817 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-01-10 | Common Stock | $33.03 | A | 4593 | Acquired | 2033-01-10 | Common Stock (4593) | Direct |
Footnotes
F1: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2: Represents shares underlying restricted stock units, which will vest in one installment on the first anniversary of the grant date.
F3: Represents options, which will vest in one installment on the first anniversary of the grant date.